Liquid vs. pill: new study tests easier way to take seizure drug
NCT ID NCT07176832
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested two versions of the seizure medication stiripentol (Diacomit®) in 24 healthy adults: a capsule and a liquid suspension. The goal was to see if the liquid form is absorbed by the body in a similar way to the capsule. If so, it could provide a more convenient option for children and adults with Dravet syndrome who have difficulty swallowing pills. The study also checked for side effects and how the liquid tastes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stiripentol (Diacomit®)
What this could lead to
If the oral suspension works as well as the capsule, it could offer a more convenient liquid option for people with Dravet syndrome who have trouble swallowing pills.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. It only looks at how the drug is absorbed, not whether it actually helps control seizures. The liquid form may not prove equally effective in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
3 Chemin d'Armancourt
Compiègne, 60200, France
-
EUROFINS OPTIMED, 1 rue des Essarts
Gières, 38610, France